D
Donna Masterman
Researcher at Genentech
Publications - 22
Citations - 3659
Donna Masterman is an academic researcher from Genentech. The author has contributed to research in topics: Ocrelizumab & Interferon beta-1a. The author has an hindex of 12, co-authored 22 publications receiving 2871 citations. Previous affiliations of Donna Masterman include Amgen & Hoffmann-La Roche.
Papers
More filters
Journal ArticleDOI
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Xavier Montalban,Stephen L. Hauser,Ludwig Kappos,Douglas L. Arnold,Amit Bar-Or,Giancarlo Comi,Jérôme De Seze,Gavin Giovannoni,Hans-Peter Hartung,Bernhard Hemmer,Fred D. Lublin,Kottil Rammohan,Krzysztof Selmaj,Anthony Traboulsee,Annette Sauter,Donna Masterman,Paulo Fontoura,Shibeshih Belachew,Hideki Garren,N. Mairon,Peter Chin,Jerry S. Wolinsky +21 more
TL;DR: Among patients with primary progressive multiple sclerosis, ocrelizumab was associated with lower rates of clinical and MRI progression than placebo; there was no clinically significant difference between groups in the rates of serious adverse events and serious infections.
Journal ArticleDOI
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Stephen L. Hauser,Amit Bar-Or,Giancarlo Comi,Gavin Giovannoni,Hans Peter Hartung,Bernhard Hemmer,Fred D. Lublin,Xavier Montalban,Kottil Rammohan,Krzysztof Selmaj,A. Traboulsee,Jerry S. Wolinsky,Douglas L. Arnold,Gaelle Klingelschmitt,Donna Masterman,Paulo Fontoura,Shibeshih Belachew,Peter Chin,N. Mairon,Hideki Garren,Ludwig Kappos +20 more
TL;DR: Among patients with relapsing multiple sclerosis, ocrelizumab was associated with lower rates of disease activity and progression than interferon beta‐1a over a period of 96 weeks.
Journal ArticleDOI
A Potential Role of the Curry Spice Curcumin in Alzheimer’s Disease
TL;DR: A study of curcumin in patients with AD is performed to gather information on the bioavailability, safety and tolerability of this promising agent in the treatment and/or prevention of AD.
Journal ArticleDOI
Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study.
John M. Ringman,Sally A. Frautschy,Edmond Teng,Aynun N. Begum,Jenny Bardens,Maryam Beigi,Karen H. Gylys,Vladimir Badmaev,Dennis D. Heath,Liana G. Apostolova,Verna Porter,Zeba Vanek,Gad A. Marshall,Gerhard Hellemann,Catherine A. Sugar,Donna Masterman,Thomas J. Montine,Jeffrey L. Cummings,Greg M. Cole +18 more
TL;DR: Curcumin was generally well-tolerated although three subjects on curcumin withdrew due to gastrointestinal symptoms, and preliminary data suggest limited bioavailability of this compound.
Journal ArticleDOI
Development of a Maturing T-Cell-Mediated Immune Response in Patients with Idiopathic Parkinson’s Disease Receiving r-metHuGDNF Via Continuous Intraputaminal Infusion
Suzanna M. Tatarewicz,Xin Wei,Shalini Gupta,Donna Masterman,Steven J. Swanson,Michael Moxness +5 more
TL;DR: The development of a maturing T-cell-mediated immune response was characterized in Parkinson’s disease subjects receiving recombinant human glial-derived neurotrophic factor via continuous bilateral intraputaminal infusion and two immunodominant MHC class II T- cell epitopes were predicted for the native GDNF sequence.